Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.

Na Xu,Charles H. Redfern,Michael S. Gordon,Stephen Eppler,Bert L. Lum,Caroline Trudeau

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.

2014

Na Xu
Charles H. Redfern
Michael S. Gordon
Stephen Eppler
Bert L. Lum
Caroline Trudeau

Purpose This study evaluated the potential effect of trastuzumab on the electrocardiogram (ECG) QT interval and assessed the potential pharmacokinetic interaction between trastuzumab and carboplatin. Here, we report the QT and safety results.

Keywords:

Carboplatin
QT interval
Pharmacology
Trastuzumab
Oncology
Medicine
Internal medicine
Human Epidermal Growth Factor Receptor 2
Docetaxel
Pharmacokinetics
potential effect
pharmacokinetic interaction
pharmacology toxicology
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations